- Home
- KALU vs RCUS Comparison
KALU vs RCUS Comparison
Compare KALU & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- RCUS
- Stock Information
- Founded
- KALU 1946
- RCUS 2015
- Country
- KALU United States
- RCUS United States
- Employees
- KALU N/A
- RCUS N/A
- Industry
- KALU Metal Fabrications
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- KALU Industrials
- RCUS Health Care
- Exchange
- KALU Nasdaq
- RCUS Nasdaq
- Market Cap
- KALU 1.1B
- RCUS 1.2B
- IPO Year
- KALU 1991
- RCUS 2018
- Fundamental
- Price
- KALU $71.86
- RCUS $11.07
- Analyst Decision
- KALU Buy
- RCUS Buy
- Analyst Count
- KALU 2
- RCUS 11
- Target Price
- KALU $90.00
- RCUS $31.11
- AVG Volume (30 Days)
- KALU 98.0K
- RCUS 1.1M
- Earning Date
- KALU 02-19-2025
- RCUS 02-25-2025
- Dividend Yield
- KALU 4.24%
- RCUS N/A
- EPS Growth
- KALU N/A
- RCUS N/A
- EPS
- KALU 2.87
- RCUS N/A
- Revenue
- KALU $3,024,000,000.00
- RCUS $263,000,000.00
- Revenue This Year
- KALU N/A
- RCUS $127.65
- Revenue Next Year
- KALU $4.72
- RCUS N/A
- P/E Ratio
- KALU $25.34
- RCUS N/A
- Revenue Growth
- KALU N/A
- RCUS 119.17
- 52 Week Low
- KALU $63.44
- RCUS $10.63
- 52 Week High
- KALU $102.42
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- KALU 49.76
- RCUS 34.34
- Support Level
- KALU $69.59
- RCUS $10.63
- Resistance Level
- KALU $77.11
- RCUS $13.49
- Average True Range (ATR)
- KALU 2.40
- RCUS 0.77
- MACD
- KALU 0.27
- RCUS -0.13
- Stochastic Oscillator
- KALU 40.61
- RCUS 13.88
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from United States.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.